⌘K
Loading ticker…
As of 2026-08-24, Travere Therapeutics, Inc. Common Stock (TVTX) has a 3-month relative strength percentile of 93 and a leadership percentile of 96 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 82. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 4.1%, relative volume 0.60×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
TVTX is in a stage 2 uptrend, week 12. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 12.0% / 59.2%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
TVTX is held by 27 ETFs as of May 2026. Top owner: SCHA at 0.09% weight, $20M notional. Top 3 carry $52M.
Held by 67 ETFs · $446M across latest filings · largest weight 7.67% (LFSC).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| SCHASchwab U.S. Small-Cap ETF | 0.09% | $20M | +0.03 pp |
| VTWO | 0.11% | $20M | +0.03 pp |
| VHTVanguard Health Care ETF | 0.06% | $12M | +0.03 pp |
| LFSC | 7.67% | $8M | +3.04 pp |
| SBIO | 2.77% | $4M | +1.05 pp |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| VTWG |
| 0.20% |
| $3M |
| +0.06 pp |
| SCHBSchwab U.S. Broad Market ETF | 0.01% | $3M | — |
| GSSC | 0.26% | $3M | +0.07 pp |
| ESML | 0.08% | $2M | +0.04 pp |
| VFMO | 0.10% | $2M | +0.02 pp |
Showing 10 of 27 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | TVTX Jan avg: 1.17% median: 2.92% win: 50% σ: 15.16% n: 4 2022-04-12 → 2026-07-31 | TVTX Feb avg: -4.00% median: -2.63% win: 25% σ: 8.39% n: 4 2022-04-12 → 2026-07-31 | TVTX Mar avg: -3.26% median: 0.61% win: 50% σ: 8.72% n: 4 2022-04-12 → 2026-07-31 | TVTX Apr avg: 2.71% median: -4.09% win: 40% σ: 27.05% n: 5 2022-04-12 → 2026-07-31 | TVTX May avg: -1.19% median: -7.24% win: 40% σ: 24.61% n: 5 2022-04-12 → 2026-07-31 | TVTX Jun avg: 3.91% median: 3.95% win: 60% σ: 12.98% n: 5 2022-04-12 → 2026-07-31 | TVTX Jul avg: 5.58% median: 4.39% win: 60% σ: 8.28% n: 5 2022-04-12 → 2026-07-31 | TVTX Aug avg: 2.32% median: 6.27% win: 50% σ: 14.48% n: 4 2022-04-12 → 2026-07-31 (current) | TVTX Sep avg: 9.75% median: 14.32% win: 50% σ: 39.57% n: 4 2022-04-12 → 2026-07-31 | TVTX Oct avg: 8.17% median: 6.54% win: 50% σ: 34.08% n: 4 2022-04-12 → 2026-07-31 | TVTX Nov avg: -0.51% median: -1.19% win: 50% σ: 6.22% n: 4 2022-04-12 → 2026-07-31 | TVTX Dec avg: 12.04% median: 6.19% win: 75% σ: 21.75% n: 4 2022-04-12 → 2026-07-31 |